

**AKUMS DRUGS & PHARMACEUTICALS LIMITED**

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)  
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083  
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

---

Ref: Akums/Exchange/2024-25/07

August 24, 2024

**To,  
The Listing Department  
National Stock Exchange of India Ltd  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051**

**To,  
The Listing Department  
BSE Limited  
Rotunda Building, Phiroze  
Jeejeebhoy Towers, Dalal Street,  
Fort, Mumbai – 400 001**


**Symbol: AKUMS****Scrip Code: 544222****Sub: Outcome of Board Meeting held on 24<sup>th</sup> August, 2024.**

Respected Sir/Madam,

In terms of Regulation 30 and 33 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company in its meeting held today i.e. 24<sup>th</sup> August, 2024 has inter-alia considered and approved the following:

1. The Un-audited (Standalone & Consolidated) Financial Results for the quarter ended 30th June, 2024, along with the Limited Review Reports thereon, as received from the Statutory Auditors Walker Chandio & Co. LLP, Chartered Accountants. Copies of such financial results along with the Limited Review Reports thereon are enclosed herewith as **Annexure-A**.
2. Authorization of Key Managerial Personnel to determine materiality of an event or information and its disclosures to stock exchanges. The details are enclosed herewith as **Annexure-B**.
3. Appointment of Mr. Amrut Medhekar as a Chief Executive Officer – CDMO Business with effect from 24<sup>th</sup> August, 2024.

Details required for the appointment of Chief Executive Officer under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13th July 2023 are provided herein as **Annexure-C**.



ISO 9001 : 2015  
ISO 14001 : 2015  
ISO 17025 : 2005 (NABL)

WHO-GMP  
US : NSF  
H A C C P



**AKUMS DRUGS & PHARMACEUTICALS LIMITED**

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)  
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083  
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

---

4. Investment of INR 225 Cr. to set up manufacturing facility(ies) through Qualymed Pharma Pvt. Ltd, wholly owned subsidiary of the company, in Jammu & Kashmir, wherein Government of India had announced an industry promotion scheme for Jammu & Kashmir with the title of 'New Central Sector Scheme for Industrial Development of Union Territory of Jammu & Kashmir'. Any further information in this connection will be submitted with the exchanges in due course.


The Board Meeting commenced at 03:00 PM and concluded at 05:10 PM.

This is for your kind information and record.

Thanking You

For **Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik  
Company Secretary & Compliance Officer



ISO 9001 : 2015  
ISO 14001 : 2015  
ISO 17025 : 2005 (NABL)

WHO-GMP  
US : NSF  
H A C C P



# Walker Chandiook & Co LLP

---

Walker Chandiook & Co LLP  
L 41, Connaught Circus,  
Outer Circle,  
New Delhi – 110 001  
India  
T +91 11 45002219  
F +91 11 42787071

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Akums Drugs and Pharmaceuticals Limited**

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Akums Drugs and Pharmaceuticals Limited ('the Company') for the quarter ended 30 June 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). Attention is drawn to the fact that the figures for the preceding quarter and corresponding quarter ended 31 March 2024 and 30 June 2023 respectively as reported in the Statement have been approved by the Company's Board of Directors, but have not been subjected to audit or review.
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



---

Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

---

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India

# Walker Chandiook & Co LLP

## Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Walker Chandiook & Co LLP**  
Chartered Accountants  
Firm Registration No: 001076N/N500013

*Tarun*

**Tarun Gupta**  
Partner  
Membership No. 507892  
UDIN: 24507892BKEIWL1127



Place: New Delhi  
Date: 24 August 2024

**Chartered Accountants**

**Statement of unaudited standalone financial results for the quarter ended 30 June 2024**

(₹ in million, unless otherwise stated)

S. No.	Particulars	Quarter ended			Year ended
		30 June 2024	31 March 2024	30 June 2023	31 March 2024
		Unaudited	Unaudited (refer note 4 and 10)	Unaudited (refer note 10)	Audited
<b>I</b>	<b>Income</b>				
	Revenue from operations	3,172.75	2,983.54	3,156.14	14,441.19
	Other income	261.76	266.64	203.98	941.21
	<b>Total income (I)</b>	<b>3,434.51</b>	<b>3,250.18</b>	<b>3,360.12</b>	<b>15,382.40</b>
<b>II</b>	<b>Expenses</b>				
	Cost of materials consumed	2,009.03	1,705.31	2,155.73	8,672.35
	Changes in inventories of finished goods and work-in-progress	(121.82)	131.00	(124.17)	64.42
	Employee benefits expense	471.80	468.03	394.52	1,752.80
	Finance costs	62.06	47.95	41.69	183.13
	Depreciation and amortisation expense	93.82	90.86	74.00	326.94
	Fair value changes to financial instruments (refer note 8)	(38.67)	852.30	2,251.30	3,577.74
	Other expenses	415.58	432.23	350.27	1,640.46
	<b>Total expenses (II)</b>	<b>2,891.80</b>	<b>3,727.68</b>	<b>5,143.34</b>	<b>16,217.84</b>
<b>III</b>	<b>Profit/ (loss) before exceptional items and tax (I-II)</b>	<b>542.71</b>	<b>(477.50)</b>	<b>(1,783.22)</b>	<b>(835.44)</b>
<b>IV</b>	Exceptional items	-	(12.89)	-	(193.89)
<b>V</b>	<b>Profit/ (loss) before tax (III-IV)</b>	<b>542.71</b>	<b>(490.39)</b>	<b>(1,783.22)</b>	<b>(1,029.33)</b>
<b>VI</b>	<b>Tax expense</b>				
	Current tax				
	for current period	125.23	47.00	121.73	469.90
	for earlier years	-	-	-	13.50
	Deferred tax (credit)/ charge	(1.27)	41.29	(8.22)	141.78
	<b>Total tax expense</b>	<b>123.96</b>	<b>88.29</b>	<b>113.51</b>	<b>625.18</b>
<b>VII</b>	<b>Profit/ (loss) for the quarter/ year (V-VI)</b>	<b>418.75</b>	<b>(578.68)</b>	<b>(1,896.73)</b>	<b>(1,654.51)</b>
<b>VIII</b>	<b>Other comprehensive income</b>				
	Items that will not be reclassified to statement of profit and loss				
	Re-measurement gains/(losses) on defined benefit plans	3.07	2.67	(2.21)	(29.07)
	Tax effect relating to these items	(0.77)	(0.67)	0.56	7.32
<b>IX</b>	<b>Total comprehensive income for the quarter/ year (VII+VIII)</b> (comprising profit/ (loss) for the quarter/ year and other comprehensive income, net of tax)	<b>421.05</b>	<b>(576.68)</b>	<b>(1,898.38)</b>	<b>(1,676.26)</b>
<b>X</b>	Paid-up share capital (net off shares held by ESOP trust) (refer note 6)	286.13	286.13	286.13	286.13
<b>XI</b>	Other equity				1,152.65
<b>XII</b>	Earning per share (EPS) (face value of ₹ 2/- each) (in ₹)*				
	Basic and diluted	2.93	(4.04)	(13.26)	(11.56)

\*EPS for the quarters have not been annualised

**Notes:**

- The above standalone financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on 24 August 2024.
- These standalone financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended and prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and SEBI circular dated 5 July 2016.
- These standalone financial results for quarter ended 30 June 2024 have been subjected to limited review by the statutory auditors of the Company. The limited review report does not contain any qualifications.
- Figures for the quarter ended 31 March 2024 are the balancing figures between audited figures for the full financial year ended 31 March 2024 and the management certified year to date figures upto the nine months period ended 31 December 2023.
- Subsequent to the quarter ended 30 June 2024, the Company has completed its Initial Public Offer (IPO) of 27,368,143 equity shares of face value of ₹ 2 each at an issue price of ₹ 679 per share (including share premium of ₹ 677 per share). A discount of ₹ 64 per share was offered to eligible employees bidding in the employee reservation portion of 243,826 equity shares. The issue comprised of fresh issue of 10,037,708 equity shares aggregating to ₹ 6,800.00 million and offer for sale of 17,330,435 equity shares by selling shareholders, aggregating to ₹ 11,767.37 million. Pursuant to IPO, equity shares of the Company has been listed on National Stock exchange of India Limited (NSE) and BSE Limited (BSE) on 6 August 2024. Accordingly, these standalone financial results for the quarter ended 30 June 2024 have been drawn up for the first time in accordance with the SEBI listing regulations. Further, the Company will provide an update on the utilisation of IPO proceeds towards the objects of the fresh issue effective next reporting period based on actual utilisation of funds.



**Notes (cont'd):**

- 6 During the quarter ended 30 June 2024, the Company has issued 4,291,930 equity shares of face value of ₹ 2 each at an issue price of ₹ 700 per equity share (including share premium of ₹ 698 per equity share) to Akums Employee Benefit Trust ("ESOP Trust"). The ESOP trust has been treated as an extension of the Company and accordingly, shares held by ESOP Trust are netted off from the paid up share capital and calculation of earnings per share (basic and diluted) have been done accordingly. Further, all the assets, liabilities, income and expenses of the trust are accounted for as assets, liabilities, income and expenses of the Company.
- 7 The Company, in earlier years, had made investment its subsidiary companies: a) Amazing Research Laboratories Limited, b) May and Baker Pharmaceuticals Limited and c) Hygosap Pharma Private Limited (erstwhile Burroughs Welcome Pharmacia Private Limited) which were engaged in sale of branded and generic formulations. The Company as part of restructuring exercise, has shifted the business of these entities to other wholly owned subsidiaries conducting similar business by adding a division and have hived off these entities on 1 April 2024. The resultant gain/ loss on the sale of these investments is not material to the Company.
- 8 The Company in earlier years, executed a shareholders' agreement (the 'Agreement') with its promoters (Mr. Sandeep Jain and Mr. Sanjeev Jain) and Ruby QC Investments Pte. Limited (the 'Investor') wherein the Investor was given the right to require the Company to buyback its equity shares at fair market value in case the Company and/ or its promoters were not able facilitate exit to the Investor either through an 'initial public offer' or through a secondary sale to a third party. This was recorded as a put option liability in the books of accounts and was fair valued at each reporting period in accordance with applicable Indian Accounting Standards. This adjustment was recorded as fair value changes to the financial instrument in the statement of profit and loss for the Company.  
However, on 29 May 2024, the Investor has waived off these rights in entirety and post listing the Company is no longer required to buy-back the equity shares held by the investor. Hence, the fair value changes has been recorded in these standalone financial results till 29 May 2024 amounting to ₹ 38.67 million (reversal) and the put option liability existing as on the date of waiver i.e. 29 May 2024 amounting to ₹ 13,615.12 million has been reclassified from financial liabilities to other equity. This has resulted in increase in net worth of our Company from ₹ 1,438.78 million as on 31 March 2024 to ₹ 15,474.95 million as on 30 June 2024.
- 9 The Company operates in only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segment is not applicable and accordingly not made.
- 10 The standalone financial results for the quarters ended 31 March 2024 and 30 June 2023 have not been subject to limited review or audit. However, the management has exercised necessary diligence to ensure that the financial results for these quarters provide a true and fair view of the Company's affairs.

For and on behalf of Board of Directors of  
**Akums Drugs and Pharmaceuticals Limited**



**Sanjeev Jain**  
Managing Director  
DIN: 00323433

**Sandeep Jain**  
Managing Director  
DIN: 00323476

**Place:** New Delhi  
**Date:** 24 August 2024

# Walker Chandiook & Co LLP

---

Walker Chandiook & Co LLP  
L 41, Connaught Circus,  
Outer Circle,  
New Delhi – 110 001  
India  
T +91 11 45002219  
F +91 11 42787071

## Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

### To the Board of Directors of Akums Drugs and Pharmaceuticals Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Akums Drugs and Pharmaceuticals Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 30 June 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). Attention is drawn to the fact that the consolidated figures for the preceding quarter and corresponding quarter ended 31 March 2024 and 30 June 2023 respectively as reported in the Statement have been approved by the Holding Company's Board of Directors but have not been subjected to audit or review.
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

---

Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

---

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India



# Walker Chandiook & Co LLP

## Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the interim financial results of seven subsidiaries included in the Statement, whose financial information reflects total revenues of ₹ 508.01 million, total net loss after tax of ₹ 104.52 million and total comprehensive loss of ₹ 105.21 million for the quarter ended on 30 June 2024, as considered in the Statement. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

**For Walker Chandiook & Co LLP**  
Chartered Accountants  
Firm Registration No: 001076N/N500013



**Tarun Gupta**  
Partner  
Membership No. 507892  
UDIN 24507892BKEIWK3645



Place: New Delhi  
Date: 24 August 2024

**Chartered Accountants**



# Walker ChandioK & Co LLP

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

## **Annexure 1**

### **List of entities included in the consolidated financial results**

1. Akumentis Healthcare Limited
2. Pure and Cure Healthcare Private Limited
3. Maxcure Nutravedics Limited
4. Malik Lifesciences Private Limited
5. Unosource Pharma Limited
6. Akums Healthcare Limited
7. Nicholas Healthcare Limited
8. Plenteous Pharmaceuticals Limited
9. Sarvagunaushdhi Private Limited
10. Qualymed Pharma Private Limited
11. Upadhrish Reserchem LLP
12. Burroughs Welcome Pharmacia Private Limited\*
13. Amazing Research Laboratories Limited\*
14. May and Baker Pharmaceuticals Limited\*

### Step down subsidiaries

15. Medibox Pharma Private Limited (subsidiary of Maxcure Nutravedics Limited)

\* Hived off w.e.f. 01 April 2024



**Chartered Accountants**


**AKUMS DRUGS AND PHARMACEUTICALS LIMITED**  
 Regd. Office: 304, Mohan Place, LSC, C-Block, Saraswati Vihar, Delhi-110034  
 CIN: U24239DL2004PLC125888  
 Email Id: cs@akums.net; Website: www.akums.in

**Statement of unaudited consolidated financial results for the quarter ended 30 June 2024**

(₹ in million, unless otherwise stated)

S. No.	Particulars	Quarter ended			Year ended
		30 June 2024	31 March 2024	30 June 2023	31 March 2024
		Unaudited	Unaudited (refer note 8 and 9)	Unaudited (refer note 9)	Audited
<b>I</b>	<b>Income</b>				
	Revenue from operations	10,191.13	9,442.09	9,698.86	41,781.82
	Other income	65.46	102.41	80.94	340.25
	<b>Total income</b>	<b>10,256.59</b>	<b>9,544.50</b>	<b>9,779.80</b>	<b>42,122.07</b>
<b>II</b>	<b>Expenses</b>				
	Cost of materials consumed	5,594.96	5,132.99	5,448.47	22,783.70
	Purchase of stock-in-trade	408.55	634.88	606.55	2,595.27
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(43.48)	(74.72)	(119.46)	123.40
	Employee benefits expense	1,762.23	1,639.54	1,565.59	6,468.64
	Finance costs	130.21	123.77	121.49	506.14
	Depreciation and amortisation expense	340.64	339.53	297.17	1,256.40
	Fair value changes to financial instruments	(38.67)	852.30	2,251.30	3,577.74
	Other expenses	1,227.37	1,227.21	1,199.10	5,003.22
	<b>Total expenses</b>	<b>9,381.81</b>	<b>9,875.50</b>	<b>11,370.21</b>	<b>42,314.51</b>
<b>III</b>	<b>Profit/ (loss) before exceptional items and tax (I-II)</b>	<b>874.78</b>	<b>(331.00)</b>	<b>(1,590.41)</b>	<b>(192.44)</b>
	Exceptional items	-	(2.17)	(2.48)	260.34
<b>IV</b>	<b>Profit/ (loss) before tax for the quarter/ year</b>	<b>874.78</b>	<b>(328.83)</b>	<b>(1,587.93)</b>	<b>(452.78)</b>
<b>V</b>	<b>Tax expense</b>				
	Current tax				
	for current period	187.55	81.18	300.48	740.25
	for earlier years	-	(0.32)	-	15.18
	Deferred tax charge/ (credit)	75.15	(15.01)	(14.14)	166.67
	Adjustment on account of merger :-				
	Income-tax for earlier years	-	-	-	(182.90)
	Deferred tax (credit)	-	-	-	(1,199.88)
		<b>262.70</b>	<b>65.85</b>	<b>286.34</b>	<b>(460.68)</b>
<b>VI</b>	<b>Profit/ (loss) for the quarter/ year (IV-V)</b>	<b>612.08</b>	<b>(394.68)</b>	<b>(1,874.27)</b>	<b>7.90</b>
<b>VII</b>	<b>Other comprehensive income</b>				
	- Items that will not be reclassified to profit and loss	7.96	5.42	(4.53)	(50.50)
	- income-tax on items that will not be reclassified to profit and loss	(1.67)	(1.63)	1.27	13.72
	<b>Other comprehensive income, net of tax</b>	<b>6.29</b>	<b>3.79</b>	<b>(3.26)</b>	<b>(36.78)</b>
<b>VIII</b>	<b>Total comprehensive income for the quarter/ year (VI+VII)</b> (comprising profit/ (loss) for the quarter/ year and other comprehensive income, net of tax)	<b>618.37</b>	<b>(390.89)</b>	<b>(1,877.53)</b>	<b>(28.88)</b>
<b>IX</b>	<b>Profit/ (loss) for the quarter/ year attributable to:</b>				
	Owners of the Parent	601.71	(413.20)	(1,882.28)	(40.35)
	Non controlling interest	10.37	18.52	8.01	48.25
<b>X</b>	<b>Other comprehensive income for the quarter/ year attributable to:</b>				
	Owners of the Parent	6.30	3.76	(3.00)	(36.56)
	Non controlling interest	(0.01)	0.03	(0.26)	(0.22)
<b>XI</b>	<b>Total comprehensive income for the quarter/ year attributable to:</b>				
	Owners of the Parent	608.01	(409.44)	(1,885.28)	(76.91)
	Non controlling interest	10.36	18.55	7.75	48.03
<b>XII</b>	Paid-up share capital (net off shares held by ESOP trust) (refer note 4)	286.13	286.13	286.13	286.13
<b>XIII</b>	Other equity				6,808.85
<b>XIV</b>	Earning per share (EPS) (face value of ₹ 2/- each) (in ₹)*	4.21	(2.89)	(13.16)	(0.28)
	Basic and diluted				

\*EPS for the quarters have not been annualised



*[Handwritten signature]*

*[Handwritten signature]*



**UNAUDITED CONSOLIDATED SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES**


The Group is primarily engaged in three business segments a) Contract Development and Manufacturing operations (CDMO); b) Active Pharmaceutical Ingredient (API) and c) Branded and Generic formulations. Disclosures as per Indian Accounting Standard (Ind AS-108) "Operating Segment" has been disclosed herewith :

(₹ in million, unless otherwise stated)

Particulars	Quarter ended			Year ended
	30 June 2024	31 March 2024	30 June 2023	31 March 2024
	Unaudited	Unaudited (refer note 8 and 9)	Unaudited (refer note 9)	Audited
<b>I. Revenue from operations (including inter-segment)</b>				
a) CDMO	8,411.05	7,990.30	8,285.77	36,196.32
b) API	818.85	740.04	571.74	2,784.29
c) Branded and generic formulations	1,674.17	1,486.50	1,912.79	6,995.40
	<b>10,904.07</b>	<b>10,216.84</b>	<b>10,770.30</b>	<b>45,976.01</b>
<b>II. Revenue from operations (external customers)</b>				
a) CDMO	7,820.17	7,315.80	7,404.55	32,663.48
b) API	696.86	640.22	381.55	2,125.16
c) Branded and generic formulations	1,674.10	1,486.07	1,912.76	6,993.18
<b>Revenue from Operations</b>	<b>10,191.13</b>	<b>9,442.09</b>	<b>9,698.86</b>	<b>41,781.82</b>
<b>III. Segment results before depreciation*</b>				
a) CDMO	1,211.54	805.35	1,068.44	4,866.92
b) API	(121.60)	(79.84)	(87.78)	(455.14)
c) Branded and generic formulations	171.16	194.82	73.81	590.58
<b>IV. Segment results**</b>				
a) CDMO	937.26	535.07	842.47	3,886.14
b) API	(192.67)	(149.76)	(157.39)	(736.53)
c) Branded and generic formulations	159.00	182.80	53.82	525.88
<b>Sub total</b>	<b>903.59</b>	<b>568.11</b>	<b>738.90</b>	<b>3,675.49</b>
Unallocated corporate expenses (net of unallocated income)	40.78	(833.09)	(2,249.19)	(3,552.23)
Interest income	43.84	41.12	22.83	120.00
Finance costs	(113.43)	(107.14)	(102.95)	(435.70)
<b>Profit/ (loss) before exceptional items and tax</b>	<b>874.78</b>	<b>(331.00)</b>	<b>(1,590.41)</b>	<b>(192.44)</b>
Exceptional items	-	(2.17)	(2.48)	260.34
<b>Profit/ (loss) before tax</b>	<b>874.78</b>	<b>(328.83)</b>	<b>(1,587.93)</b>	<b>(452.78)</b>
Tax expenses	262.70	65.85	286.34	(460.68)
<b>Profit/ (loss) for the quarter/ year</b>	<b>612.08</b>	<b>(394.68)</b>	<b>(1,874.27)</b>	<b>7.90</b>
<b>V. Segment assets</b>				
a) CDMO	24,870.35	24,318.00	25,399.79	24,318.00
b) API	4,853.93	4,680.03	4,863.41	4,680.03
c) Branded and generic formulations	2,676.71	2,825.96	3,192.94	2,825.96
Less :- Inter-segment eliminations	(883.73)	(783.76)	(1,511.46)	(783.76)
<b>Segment assets</b>	<b>31,517.26</b>	<b>31,040.23</b>	<b>31,944.68</b>	<b>31,040.23</b>
Un-allocated corporate assets	4,488.87	4,123.42	2,049.83	4,123.42
<b>Total assets</b>	<b>36,006.13</b>	<b>35,163.65</b>	<b>33,994.51</b>	<b>35,163.65</b>
<b>VI. Segment liabilities</b>				
a) CDMO	6,556.35	7,401.31	8,791.28	7,401.31
b) API	910.29	423.63	697.86	423.63
c) Branded and generic formulations	2,344.15	2,226.73	2,389.82	2,226.73
Less :- Inter-segment eliminations	(883.73)	(783.76)	(1,511.46)	(783.76)
<b>Segment liabilities</b>	<b>8,927.06</b>	<b>9,267.91</b>	<b>10,367.50</b>	<b>9,267.91</b>
Un-allocated corporate liabilities	5,640.72	18,690.88	18,419.09	18,690.88
<b>Total liabilities</b>	<b>14,567.78</b>	<b>27,958.79</b>	<b>28,786.59</b>	<b>27,958.79</b>

\* Segment results before depreciation is calculated as the sum of profit/ (loss) before tax, exceptional items, finance costs, fair value changes to financial instruments and depreciation and amortisation expense.

\*\* Segment results is calculated as segment results before depreciation less finance cost pertaining to segments and depreciation and amortisation expense.



*Handwritten signature*

*Handwritten signature*



**Notes :**

- 1 The above consolidated financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on 24 August 2024.
- 2 The above consolidated financial results of Akums Drugs and Pharmaceuticals Limited (the 'Holding company' or 'Parent'), together with its subsidiaries (collectively the 'Group') have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended and prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and SEBI circular dated 5 July 2016.
- 3 These consolidated financial results for quarter ended 30 June 2024 have been subjected to limited review by the statutory auditors of the Group. The limited review report does not contain any qualifications.
- 4 Subsequent to the quarter ended 30 June 2024, the Holding Company has completed its Initial Public Offer (IPO) of 27,368,143 equity shares of face value of ₹ 2 each at an issue price of ₹ 679 per share (including share premium of ₹ 677 per share). A discount of ₹ 64 per share was offered to eligible employees bidding in the employee reservation portion of 243,826 equity shares. The issue comprised of fresh issue of 10,037,708 equity shares aggregating to ₹ 6,800.00 million and offer for sale of 17,330,435 equity shares by selling shareholders, aggregating to ₹ 11,767.37 million. Pursuant to IPO, equity shares of the Holding Company has been listed on National Stock exchange of India Limited (NSE) and BSE Limited (BSE) on 6 August 2024. Accordingly, these consolidated financial results for the quarter ended 30 June 2024 have been drawn up for the first time in accordance with the SEBI listing regulations. Further, the Holding Company will provide an update on the utilisation of IPO proceeds towards the objects of the fresh issue effective next reporting period based on actual utilisation of funds.
- 5 During the quarter ended 30 June 2024, the Holding Company has issued 4,291,930 equity shares of face value of ₹ 2 each at an issue price of ₹ 700 per equity share (including share premium of ₹ 698 per equity share) to Akums Employee Benefit Trust ("ESOP Trust"). The ESOP trust has been treated as an extension of the Holding Company and accordingly, shares held by ESOP Trust are netted off from the paid-up share capital. The calculation of earnings per share (basic and diluted) have also been done post netting off of the shares held by ESOP trust.
- 6 The Holding Company in earlier years, executed a shareholders' agreement (the 'Agreement') with its promoters (Mr. Sandeep Jain and Mr. Sanjeev Jain) and Ruby QC Investments Pte. Limited (the 'Investor') wherein the Investor was given the right to require the Holding Company to buyback its equity shares at fair market value in case the Holding Company and/or its promoters was not able facilitate exit to the Investor either through an 'initial public offer' or through a secondary sale to a third party. This was recorded as a put option liability in the books of accounts and was fair valued at each reporting period in accordance with applicable Indian Accounting Standards. This adjustment was recorded as fair value changes to the financial instrument in the consolidated statement of profit and loss for the group.  
However, on 29 May 2024, the Investor have waived off these rights in entirety and accordingly, the Holding Company is no longer required to buyback the equity shares held by the investor. Hence, the fair value changes has been recorded in these consolidated financial results till 29 May 2024 amounting to ₹ 38.67 million (reversal) and the put option liability existing as on the date of waiver i.e. 29 May 2024 amounting to ₹ 13,615.12 million has been reclassified from financial liabilities to other equity. This has resulted in increase in net worth of the Group from ₹ 7,204.86 million as on 31 March 2024 to ₹ 21,438.35 million as on 30 June 2024.
- 7 The Group, in earlier years, had investments in Amazing Research Laboratories Limited, May and Baker Pharmaceuticals Limited and Hygosap Pharma Private Limited (erstwhile Burroughs Welcome Pharmacia Private Limited) which were engaged in sale of branded and generic formulations, the business of which have been internally transferred while the net assets have moved out of the group. The impact of sale of net assets in these group companies is not material to the group.
- 8 Figures for the quarter ended 31 March 2024 are the balancing figures between audited figures for the full financial year ended 31 March 2024 and the management certified year to date figures upto the nine months period ended 31 December 2023.
- 9 The consolidated financial results for the quarters ended 31 March 2024 and 30 June 2023 have not been subject to limited review or audit. However, the management has exercised necessary diligence to ensure that the consolidated financial results for these periods provide a true and fair view of the Group's affairs.



Place: New Delhi  
Date: 24 August 2024



For and on behalf of Board of Directors of  
**Akums Drugs and Pharmaceuticals Limited**

**Sanjeev Jain**  
Managing Director  
DIN: 00323433

**Sandeep Jain**  
Managing Director  
DIN: 00323476

## AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)  
 Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083  
 Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

### Annexure B

Key Managerial Personnel of the Company severally authorised for the purpose of determination of the materiality of an event or information to the Stock Exchange(s):

Sr. No.	Name and Designation	Contact Details
1.	Mr. Sanjeev Jain Managing Director	011-69041000 <a href="mailto:sjain@akums.net">sjain@akums.net</a>
2.	Mr. Sandeep Jain Managing Director	+91-1334234327 <a href="mailto:sandeep@akums.in">sandeep@akums.in</a>

Key Managerial Personnel of the Company are severally authorised for the purpose of disclosure of the material event or information to the Stock Exchange(s):

Sr. No.	Name and Designation	Contact Details
1.	Mr. Sanjeev Jain Managing Director	011-69041000 <a href="mailto:sjain@akums.net">sjain@akums.net</a>
2.	Mr. Sandeep Jain Managing Director	+91-1334234327 <a href="mailto:sandeep@akums.in">sandeep@akums.in</a>
3.	Mr. Sumeet Sood Chief Financial Officer	011-69041000 <a href="mailto:sumeet.sood@akums.net">sumeet.sood@akums.net</a>
4.	Mr. Dharamvir Malik Company Secretary & Compliance Officer	011-69041000 <a href="mailto:dharamvir.malik@akums.net">dharamvir.malik@akums.net</a>



ISO 9001 : 2015  
 ISO 14001 : 2015  
 ISO 17025 : 2005 (NABL)

WHO-GMP  
 US : NSF  
 H A C C P



## AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)  
 Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083  
 Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

### Annexure C

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, <del>resignation,</del> <del>removal, death, or otherwise</del>	<p>Mr. Amrut Medhekar has been appointed as a Chief Executive Officer – CDMO Business.</p> <p>Mr. Medhekar will report to Mr. Sanjeev Jain and Mr. Sandeep Jain, Managing Directors of the company.</p>
2.	Date of appointment	24.08.2024
3.	Terms of appointment	As per Letter of Appointment
4.	Brief profile	<p>Mr. Medhekar brings over 27+ years of rich pharmaceutical experience.</p> <p>Mr. Medhekar has the following mentioned professional qualifications:</p> <ol style="list-style-type: none"> <li>1. Bachelor in Science</li> <li>2. MBA (Marketing)</li> <li>3. Executive MBA</li> <li>4. IIM- Ahmedabad</li> <li>5. Executive Program in Finance from XLRI</li> </ol> <p>He has an extensive experience in strategic planning, profit &amp; loss management, building of highly engaging &amp; productive team, digitization and budgetary control.</p>
5.	Disclosure of relationships between directors (in case of appointment of a director)	NA